QQQ   397.83 (+3.01%)
AAPL   171.18 (+3.54%)
MSFT   334.92 (+2.68%)
FB   322.81 (+1.55%)
GOOGL   2,945.39 (+2.87%)
AMZN   3,523.29 (+2.80%)
TSLA   1,051.75 (+4.24%)
NVDA   324.27 (+7.96%)
BABA   125.54 (+1.57%)
NIO   33.12 (+2.41%)
CGC   10.64 (+4.83%)
AMD   144.85 (+4.16%)
GE   97.55 (+1.60%)
MU   85.83 (+4.10%)
T   23.08 (-0.86%)
F   19.96 (+3.85%)
DIS   150.81 (+0.29%)
PFE   51.72 (+0.47%)
AMC   31.04 (+7.82%)
ACB   6.38 (+6.87%)
BA   208.83 (+1.43%)
QQQ   397.83 (+3.01%)
AAPL   171.18 (+3.54%)
MSFT   334.92 (+2.68%)
FB   322.81 (+1.55%)
GOOGL   2,945.39 (+2.87%)
AMZN   3,523.29 (+2.80%)
TSLA   1,051.75 (+4.24%)
NVDA   324.27 (+7.96%)
BABA   125.54 (+1.57%)
NIO   33.12 (+2.41%)
CGC   10.64 (+4.83%)
AMD   144.85 (+4.16%)
GE   97.55 (+1.60%)
MU   85.83 (+4.10%)
T   23.08 (-0.86%)
F   19.96 (+3.85%)
DIS   150.81 (+0.29%)
PFE   51.72 (+0.47%)
AMC   31.04 (+7.82%)
ACB   6.38 (+6.87%)
BA   208.83 (+1.43%)
QQQ   397.83 (+3.01%)
AAPL   171.18 (+3.54%)
MSFT   334.92 (+2.68%)
FB   322.81 (+1.55%)
GOOGL   2,945.39 (+2.87%)
AMZN   3,523.29 (+2.80%)
TSLA   1,051.75 (+4.24%)
NVDA   324.27 (+7.96%)
BABA   125.54 (+1.57%)
NIO   33.12 (+2.41%)
CGC   10.64 (+4.83%)
AMD   144.85 (+4.16%)
GE   97.55 (+1.60%)
MU   85.83 (+4.10%)
T   23.08 (-0.86%)
F   19.96 (+3.85%)
DIS   150.81 (+0.29%)
PFE   51.72 (+0.47%)
AMC   31.04 (+7.82%)
ACB   6.38 (+6.87%)
BA   208.83 (+1.43%)
QQQ   397.83 (+3.01%)
AAPL   171.18 (+3.54%)
MSFT   334.92 (+2.68%)
FB   322.81 (+1.55%)
GOOGL   2,945.39 (+2.87%)
AMZN   3,523.29 (+2.80%)
TSLA   1,051.75 (+4.24%)
NVDA   324.27 (+7.96%)
BABA   125.54 (+1.57%)
NIO   33.12 (+2.41%)
CGC   10.64 (+4.83%)
AMD   144.85 (+4.16%)
GE   97.55 (+1.60%)
MU   85.83 (+4.10%)
T   23.08 (-0.86%)
F   19.96 (+3.85%)
DIS   150.81 (+0.29%)
PFE   51.72 (+0.47%)
AMC   31.04 (+7.82%)
ACB   6.38 (+6.87%)
BA   208.83 (+1.43%)
NASDAQ:ADVM

Adverum Biotechnologies News Headlines

$1.76
-0.01 (-0.56%)
(As of 12/7/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.76
$1.84
50-Day Range
$1.74
$2.40
52-Week Range
$1.69
$14.79
Volume
1.29 million shs
Average Volume
1.98 million shs
Market Capitalization
$172.75 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.16

Media Mentions By Week



Adverum Biotechnologies Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ADVM
News Sentiment

0.51

0.34

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ADVM Articles
This Week

5

1

ADVM Articles
Average Week

Get Adverum Biotechnologies News Delivered to You Automatically

Sign up to receive the latest news and ratings for ADVM and its competitors with MarketBeat's FREE daily newsletter.

Adverum Biotechnologies (NASDAQ:ADVM) News Headlines Today

SourceHeadline
marketbeat.com logoAdverum Biotechnologies (NASDAQ:ADVM) Downgraded to Hold at Zacks Investment Research
marketbeat.com - December 7 at 4:32 PM
finance.yahoo.com logoAdverum Biotechnologies Appoints Rupert D’Souza, Ph.D., M.B.A. as Chief Financial Officer
finance.yahoo.com - December 6 at 1:44 PM
MarketBeat logoContrasting Adaptive Biotechnologies (NASDAQ:ADPT) & Adverum Biotechnologies (NASDAQ:ADVM)
americanbankingnews.com - December 6 at 5:08 AM
MarketBeat logoAdverum Biotechnologies, Inc. (NASDAQ:ADVM) Sees Significant Decrease in Short Interest
americanbankingnews.com - December 4 at 3:34 AM
finance.yahoo.com logoMoore Kuehn, PLLC Encourages Investors of Adverum Biotechnologies, Inc. to Contact Law Firm
finance.yahoo.com - November 30 at 10:51 AM
MarketBeat logoAdverum Biotechnologies, Inc. (NASDAQ:ADVM) Receives Consensus Rating of "Hold" from Analysts
americanbankingnews.com - November 26 at 11:36 AM
MarketBeat logoAdverum Biotechnologies, Inc. (NASDAQ:ADVM) Expected to Post Earnings of -$0.42 Per Share
americanbankingnews.com - November 25 at 9:10 PM
MarketBeat logoComparing aTyr Pharma (NASDAQ:LIFE) & Adverum Biotechnologies (NASDAQ:ADVM)
americanbankingnews.com - November 23 at 7:24 AM
nasdaq.com logoIndependent Director James Scopa Just Sold A Bunch Of Shares In Adverum Biotechnologies, Inc. (NASDAQ:ADVM)
nasdaq.com - November 19 at 8:16 PM
MarketBeat logoInsider Selling: Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Director Sells 50,000 Shares of Stock
americanbankingnews.com - November 17 at 5:24 PM
finance.yahoo.com logoHere's What Adverum Biotechnologies, Inc.'s (NASDAQ:ADVM) Shareholder Ownership Structure Looks Like
finance.yahoo.com - November 17 at 10:09 AM
fool.com logoAdverum Biotechnologies, Inc.(ADVM)
fool.com - November 12 at 8:55 AM
finance.yahoo.com logoAdverum Reports Third Quarter 2021 Results
finance.yahoo.com - November 4 at 8:38 PM
finance.yahoo.com logoAdverum Presents Clinical Data on ADVM-022 at the American Society of Retina Specialists 39th Annual Scientific Meeting
finance.yahoo.com - October 9 at 2:40 PM
finance.yahoo.com logoAdverum's Single Dose Wet AMD Gene Therapy Shows Robust Two Year Durability, Safety
finance.yahoo.com - October 4 at 12:39 PM
finance.yahoo.com logoCompanies Like Adverum Biotechnologies (NASDAQ:ADVM) Are In A Position To Invest In Growth
finance.yahoo.com - October 3 at 11:37 AM
marketwatch.com logoAdverum Biotechnologies Shares Up on Favorable Long-Term Data for ADVM-022
marketwatch.com - October 2 at 12:31 AM
finance.yahoo.com logoAdverum Presents 2-Year OPTIC Data Demonstrating Sustained Durability and Promising Safety Profile from Single Intravitreal Injection of ADVM-022 in Wet AMD Patients Who Previously Required Frequent Anti-VEGF Injections
finance.yahoo.com - October 1 at 7:30 PM
finance.yahoo.com logoAdverum to Present Data from ADVM-022 Clinical Trials at Upcoming Medical Conferences
finance.yahoo.com - September 27 at 9:05 AM
finance.yahoo.com logoAdverum Appoints Global Regulatory Leader Jim Wang, Ph.D., as Senior Vice President, Head of Regulatory Affairs
finance.yahoo.com - August 23 at 11:47 AM
nasdaq.com logoBullish insiders at Adverum Biotechnologies, Inc. (NASDAQ:ADVM) loaded up on US$613k of stock earlier this year
nasdaq.com - August 22 at 3:20 PM
finance.yahoo.com logoInsiders might want to re-evaluate their US$613k stock purchase as Adverum Biotechnologies, Inc. (NASDAQ:ADVM) drops to US$217m
finance.yahoo.com - August 19 at 7:25 AM
finance.yahoo.com logoWhy Adverum Biotechnologies (ADVM) Might Surprise This Earnings Season
finance.yahoo.com - August 6 at 2:19 PM
finance.yahoo.com logoAdverum Reports Second Quarter 2021 Results
finance.yahoo.com - August 5 at 6:52 PM
benzinga.com logoWhere Adverum Biotechnologies Stands With Analysts
benzinga.com - July 23 at 8:17 PM
finance.yahoo.com logoAdverum Provides Update on ADVM-022 and the INFINITY Trial in Patients with Diabetic Macular Edema
finance.yahoo.com - July 22 at 6:21 PM
benzinga.com logoUnderstanding Adverum Biotechnologies's Unusual Options Activity
benzinga.com - July 22 at 12:27 AM
finance.yahoo.com logoAdverum Announces Appointment of Jon Williams, Ph.D., as Vice President, Clinical Affairs
finance.yahoo.com - July 1 at 9:45 AM
finance.yahoo.com logoAdverum Biotechnologies (ADVM) Moves to Buy: Rationale Behind the Upgrade
finance.yahoo.com - June 28 at 5:38 PM
finance.yahoo.com logoIf You Had Bought Adverum Biotechnologies' (NASDAQ:ADVM) Shares A Year Ago You Would Be Down 85%
finance.yahoo.com - June 21 at 7:27 AM
finance.yahoo.com logoWhy Adverum Biotechnologies Stock Sank in May
finance.yahoo.com - June 15 at 7:38 AM
finance.yahoo.com logoAdverum Appoints CMO and CSO
finance.yahoo.com - June 1 at 8:53 AM
finance.yahoo.com logoAre Options Traders Betting on a Big Move in Adverum (ADVM) Stock?
finance.yahoo.com - May 18 at 11:31 AM
finance.yahoo.com logoAdverum Biotechnologies (ADVM) is Oversold: Can It Recover?
finance.yahoo.com - May 17 at 12:39 PM
uk.finance.yahoo.com logoAdverum Biotechnologies Stock Is Estimated To Be Possible Value Trap
uk.finance.yahoo.com - May 16 at 6:31 AM
finance.yahoo.com logoAdverum Stockholders Re-Elect All Adverum Director Nominees at 2021 Annual Meeting
finance.yahoo.com - May 12 at 4:06 PM
finance.yahoo.com logoThe Sonic Fund II, L.P. Comments on Preliminary Voting Results of Adverum Annual Meeting
finance.yahoo.com - May 12 at 4:06 PM
finance.yahoo.com logoThe Sonic Fund II, L.P. Issues Statement to Adverum Stockholders
finance.yahoo.com - May 11 at 6:17 PM
finance.yahoo.com logoThe Sonic Fund II, L.P. Reminds Adverum Stockholders to Vote for Its Three Independent Director Nominees at May 12 Annual Meeting
finance.yahoo.com - May 10 at 2:13 PM
finance.yahoo.com logoAdverum Issues Statement Regarding Upcoming Annual Meeting of Stockholders
finance.yahoo.com - May 10 at 9:12 AM
nasdaq.com logoAdverum Biotechnologies'(NASDAQ:ADVM) Share Price Is Down 81% Over The Past Year.
nasdaq.com - May 9 at 1:53 PM
finance.yahoo.com logoAdverum Biotechnologies (ADVM) Reports Q1 Loss, Tops Revenue Estimates
finance.yahoo.com - May 6 at 10:03 PM
finance.yahoo.com logoAdverum Reports First Quarter 2021 Results
finance.yahoo.com - May 6 at 5:02 PM
finance.yahoo.com logoGlass Lewis Joins ISS In Recommending Adverum Shareholders Vote for All Three Independent Sonic Director Nominees
finance.yahoo.com - May 6 at 12:02 PM
seekingalpha.com logoAdverum Biotechnologies: One Adverse Event Too Many
seekingalpha.com - May 4 at 7:00 PM
finance.yahoo.com logoISS Recommends Adverum Stockholders Vote to Elect Sonic’s Three Independent, Highly Qualified Nominees
finance.yahoo.com - May 4 at 8:51 AM
finance.yahoo.com logoAdverum's Wet AMD Gene Therapy Shows Long Term Benefit In Treatment-Experienced Patients
finance.yahoo.com - May 3 at 1:07 PM
msn.com logoBRIEF-The Sonic Fund Ii, L.P. Comments On Adverum Update Regarding Infinity Phase 2 Trial Of Advm-022
msn.com - April 29 at 4:15 PM
finance.yahoo.com logoWhy Adverum Biotechnologies Stock Is Imploding Today
finance.yahoo.com - April 29 at 4:15 PM
finance.yahoo.com logoThe Sonic Fund II, L.P. Comments on Adverum Biotechnologies Update Regarding INFINITY Phase 2 Trial of ADVM-022
finance.yahoo.com - April 29 at 4:15 PM
finance.yahoo.com logoAdverum's Stock Crashes After DME Gene Therapy Trial Derails On One Patient's Serious Adverse Event
finance.yahoo.com - April 29 at 9:36 AM
Get Adverum Biotechnologies News Delivered to You Automatically

Sign up to receive the latest news and ratings for ADVM and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 12/7/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.